| Identification | Back Directory | [Name]
CI-1044 | [CAS]
197894-84-1 | [Synonyms]
CI-1044 PD-189659 CI-1044
(CI1044) 3-Pyridinecarboxamide, N-[(3R)-9-amino-3,4,6,7-tetrahydro-4-oxo-1-phenylpyrrolo[3,2,1-jk][1,4]benzodiazepin-3-yl]- | [Molecular Formula]
C23H19N5O2 | [MDL Number]
MFCD12756374 | [MOL File]
197894-84-1.mol | [Molecular Weight]
397.43 |
| Chemical Properties | Back Directory | [Boiling point ]
773.2±60.0 °C(Predicted) | [density ]
1.43±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 125 mg/mL (314.52 mM) | [form ]
Solid | [pka]
11.27±0.40(Predicted) | [color ]
Light yellow to yellow |
| Hazard Information | Back Directory | [Uses]
(+)-CI 1044, is an orally active PDE4 inhibitor. | [in vivo]
TNF-α production is dose-dependently inhibited by CI-1044, rolipram and cilomilast with ID50s of 0.4, 1.4 and 1.6 mg/kg respectively following single oral administration. Following repeated administration with CI-1044, the ID50 value represents 0.5 mg/kg p.o.. CI-1044 plasma levels increase proportionally with doses ranging between 0.1 and 40 mg/kg p.o. (R2=0.878). CI-1044 dose dependently inhibits the accumulation of eosinophils in Bronchoalveolar lavages (BAL) fluids with an ID50 value of 3.25 mg/kg. A single dose treatment with CI-1044 (10 mg/kg, p.o.) 24, 8, 3 or 1 h before the antigen challenge induces 6, 56, 48 and 79% inhibition in the number of eosinophils in BAL[1]. | [IC 50]
PDE4A5: 0.29 μM (IC50); PDE4B2: 0.08 μM (IC50); PDE4C2: 0.56 μM (IC50); PDE4D3: 0.09 μM (IC50) |
|
|